3 Stocks Dragging The Health Care Sector Downward
All three major indices are trading down today with the
Dow Jones Industrial Average
(
^DJI
) trading down 44 points (-0.2%) at 17,874 as of Wednesday, Nov. 4, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,080 issues advancing vs. 1,836 declining with 168 unchanged.
The Health Care sector currently sits down 0.2% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the sector include
(
), down 10.2%,
(
), down 4.4%,
(
), down 4.2%,
(
), down 3.9% and
Fresenius Medical Care AG & Co. KGaA
(
), down 3.5%. A company within the sector that increased today was
(
), up 2.2%.
TheStreet would like to highlight 3 stocks pushing the sector lower today:
3.
(
) is one of the companies pushing the Health Care sector lower today. As of noon trading, Bristol-Myers Squibb Company is down $1.02 (-1.5%) to $65.06 on light volume. Thus far, 1.5 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7.8 million shares. The stock has ranged in price between $65.01-$66.14 after having opened the day at $65.81 as compared to the previous trading day's close of $66.08.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $109.7 billion and is part of the drugs industry. Shares are up 11.9% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Bristol-Myers Squibb Company a buy, no analysts rate it a sell, and 5 rate it a hold.
TheStreet Ratings rates
Bristol-Myers Squibb Company
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full
Bristol-Myers Squibb Company Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
2. As of noon trading,
(
) is down $1.54 (-1.2%) to $124.98 on light volume. Thus far, 1.5 million shares of Celgene exchanged hands as compared to its average daily volume of 5.5 million shares. The stock has ranged in price between $124.18-$127.33 after having opened the day at $126.62 as compared to the previous trading day's close of $126.52.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $100.6 billion and is part of the drugs industry. Shares are up 13.1% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Celgene a buy, no analysts rate it a sell, and 2 rate it a hold.
TheStreet Ratings rates
Celgene
as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
1. As of noon trading,
(
) is down $1.06 (-0.7%) to $161.40 on light volume. Thus far, 931,341 shares of Amgen exchanged hands as compared to its average daily volume of 4.3 million shares. The stock has ranged in price between $161.00-$163.99 after having opened the day at $162.85 as compared to the previous trading day's close of $162.46.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. Amgen has a market cap of $123.1 billion and is part of the drugs industry. Shares are up 2.0% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold.
TheStreet Ratings rates
Amgen
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider
Health Care Select Sector SPDR
(
) while those bearish on the health care sector could consider
ProShares Ultra Short Health Care
(
).